Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech/Tanox/Ciba to combine anti-IgE antibody development efforts.

Executive Summary

GENENTECH/TANOX/CIBA TO COMBINE ANTI-IGE ANTIBODY DEVELOPMENT for the treatment of allergies and allergic asthma as part of a July 9 settlement of litigation between Genentech and Tanox. Ciba is Tanox' partner for the anti-immunoglobulin E antibody research project under a 1990 agreement. The three companies plan to reach a definitive development agreement in the next six months.

You may also be interested in...

Xolair collaboration settlement

Genentech, Novartis and Tanox settle disagreements over anti-IgE antibody collaboration that includes Xolair. Genentech and Novartis each pay Tanox $3.3 mil. for development costs of TNX-901, an agent with a mechanism of action similar to Xolair; Tanox relinquishes rights to manufacture Xolair in exchange for payments for Xolair produced and accelerated debt forgiveness. The collaboration was the result of a 1996 settlement (1"The Pink Sheet" June 15, 1996, T&G-8)...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts